SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 79 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $422,822 | -48.6% | 29,120 | -25.9% | 0.00% | -66.7% |
| Q2 2023 | $822,193 | +47.1% | 39,283 | +20.6% | 0.00% | +50.0% |
| Q2 2021 | $559,000 | -6.2% | 32,575 | +22.3% | 0.00% | -33.3% |
| Q1 2021 | $596,000 | -70.6% | 26,639 | -70.8% | 0.00% | -80.0% |
| Q4 2020 | $2,027,000 | +109.6% | 91,127 | +39.2% | 0.02% | +15.4% |
| Q3 2020 | $967,000 | +221.3% | 65,484 | +222.4% | 0.01% | +160.0% |
| Q2 2020 | $301,000 | -15.2% | 20,313 | -37.2% | 0.01% | -44.4% |
| Q1 2020 | $355,000 | +327.7% | 32,356 | +73.9% | 0.01% | +800.0% |
| Q4 2018 | $83,000 | -16.2% | 18,601 | +51.3% | 0.00% | 0.0% |
| Q3 2018 | $99,000 | +11.2% | 12,298 | +20.4% | 0.00% | -50.0% |
| Q4 2017 | $89,000 | – | 10,216 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $24,631,000 | 16.36% |
| Kynam Capital Management, LP | 2,272,915 | $54,618,000 | 11.51% |
| Frazier Life Sciences Management, L.P. | 3,412,838 | $82,010,000 | 6.32% |
| Foresite Capital Management IV, LLC | 690,000 | $16,581,000 | 5.33% |
| Paradigm Biocapital Advisors LP | 1,085,142 | $26,076,000 | 3.48% |
| ACUTA CAPITAL PARTNERS, LLC | 324,614 | $7,800,000 | 3.36% |
| COMMODORE CAPITAL LP | 738,110 | $17,737,000 | 2.85% |
| SPHERA FUNDS MANAGEMENT LTD. | 822,696 | $19,769,000 | 2.74% |
| Avidity Partners Management LP | 5,586,900 | $134,253,000 | 2.73% |
| HealthCor Management, L.P. | 859,240 | $20,648,000 | 2.58% |